Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry

Documenti analoghi

• Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry
  di: Patrick Marschner, et al.
  Pubblicazione: (2026)
• Real‐world progression‐free survival and overall survival in patients with HR + / HER2 − advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study
  di: Peter A. Fasching, et al.
  Pubblicazione: (2026)
• Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
  di: Xu Liang, et al.
  Pubblicazione: (2024)
• Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
  di: Zhimin Shao, et al.
  Pubblicazione: (2024)
• Unified Geometric Theory: Derivation of the Fine Structure Constant
  di: Harbeck
  Pubblicazione: (2025)